Literature DB >> 19231180

Identification and SAR of novel diaminopyrimidines. Part 1: The discovery of RO-4, a dual P2X(3)/P2X(2/3) antagonist for the treatment of pain.

David S Carter1, Muzaffar Alam, Haiying Cai, Michael P Dillon, Anthony P D W Ford, Joel R Gever, Alam Jahangir, Clara Lin, Amy G Moore, Paul J Wagner, Yansheng Zhai.   

Abstract

P2X purinoceptors are ligand-gated ion channels whose endogenous ligand is ATP. Both the P2X(3) and P2X(2/3) receptor subtypes have been shown to play an important role in the regulation of sensory function and dual P2X(3)/P2X(2/3) antagonists offer significant potential for the treatment of pain. A high-throughput screen of the Roche compound collection resulted in the identification of a novel series of diaminopyrimidines; subsequent optimization resulted in the discovery of RO-4, a potent, selective and drug-like dual P2X(3)/P2X(2/3) antagonist.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19231180     DOI: 10.1016/j.bmcl.2009.02.003

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  19 in total

1.  P2X receptor antagonists for pain management: examination of binding and physicochemical properties.

Authors:  Rebecca J Gum; Brian Wakefield; Michael F Jarvis
Journal:  Purinergic Signal       Date:  2011-11-16       Impact factor: 3.765

Review 2.  Molecular and functional properties of P2X receptors--recent progress and persisting challenges.

Authors:  Karina Kaczmarek-Hájek; Eva Lörinczi; Ralf Hausmann; Annette Nicke
Journal:  Purinergic Signal       Date:  2012-05-01       Impact factor: 3.765

Review 3.  Medicinal chemistry of adenosine, P2Y and P2X receptors.

Authors:  Kenneth A Jacobson; Christa E Müller
Journal:  Neuropharmacology       Date:  2015-12-12       Impact factor: 5.250

Review 4.  Activation and regulation of purinergic P2X receptor channels.

Authors:  Claudio Coddou; Zonghe Yan; Tomas Obsil; J Pablo Huidobro-Toro; Stanko S Stojilkovic
Journal:  Pharmacol Rev       Date:  2011-07-07       Impact factor: 25.468

Review 5.  P2X receptors as drug targets.

Authors:  R Alan North; Michael F Jarvis
Journal:  Mol Pharmacol       Date:  2012-12-19       Impact factor: 4.436

6.  AF-353, a novel, potent and orally bioavailable P2X3/P2X2/3 receptor antagonist.

Authors:  Joel R Gever; Rothschild Soto; Robert A Henningsen; Renee S Martin; David H Hackos; Sandip Panicker; Werner Rubas; Ian B Oglesby; Michael P Dillon; Marcos E Milla; Geoffrey Burnstock; Anthony P D W Ford
Journal:  Br J Pharmacol       Date:  2010-07       Impact factor: 8.739

7.  Characterization of three diaminopyrimidines as potent and selective antagonists of P2X3 and P2X2/3 receptors with in vivo efficacy in a pain model.

Authors:  E Ballini; C Virginio; S J Medhurst; S G Summerfield; L Aldegheri; A Buson; C Carignani; Y H Chen; A Giacometti; I Lago; A J Powell; W Jarolimek
Journal:  Br J Pharmacol       Date:  2011-07       Impact factor: 8.739

8.  2',3'-O-Substituted ATP derivatives as potent antagonists of purinergic P2X3 receptors and potential analgesic agents.

Authors:  Diego Dal Ben; Anna Marchenkova; Ajiroghene Thomas; Catia Lambertucci; Andrea Spinaci; Gabriella Marucci; Andrea Nistri; Rosaria Volpini
Journal:  Purinergic Signal       Date:  2016-10-18       Impact factor: 3.765

9.  Differential expression and pharmacology of native P2X receptors in rat and primate sensory neurons.

Authors:  Alexandre Serrano; Gary Mo; Rebecca Grant; Michel Paré; Dajan O'Donnell; Xiao Hong Yu; Miroslaw J Tomaszewski; Martin N Perkins; Philippe Séguéla; Chang Qing Cao
Journal:  J Neurosci       Date:  2012-08-22       Impact factor: 6.167

Review 10.  Purinergic mechanosensory transduction and visceral pain.

Authors:  Geoffrey Burnstock
Journal:  Mol Pain       Date:  2009-11-30       Impact factor: 3.395

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.